Gastric Electrical Stimulation Has an Effect on Gastric Interstitial cells of Cajal (ICC) That is Associated With Mast Cells.
gastric electrical stimulation
gastroparesis
inflammation
interstitial cells of cajal
mast cells
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
12 Nov 2020
12 Nov 2020
Historique:
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Introduction Gastric electrical stimulation (GES) is an emerging therapy for gastric motility disorders, showing improvement of gastroparesis related symptoms in previous studies. Interstitial cells of Cajal (ICC) and mast cells have been shown to have a relevant role in gastroparesis pathogenesis. However, the exact effects of GES in those cells is relatively unknown. Methods Full thickness biopsies (FTBx) of 20 patients with refractory gastroparesis were obtained at the time of GES placement and repeated when the device was exchanged (mean of 22.5 months between biopsies). A patient-reported outcomes survey was obtained during each office visit during this period. All biopsies were stained with cluster of differentiation 117 (CD117), S100, and mast cell tryptase antibodies and were analyzed. Results Half of the patients had a significant increase of ICC during the repeated biopsy compared with baseline (p=0.01) and the other half had significant decrease in ICC levels (p=0.006) but there was no noticeable difference in mast cells counts at baseline between groups. Mast cells analysis was performed in two different groups depending on ICC change from the baseline biopsy (CD117 increase vs CD117 decrease). There was only a significant increase of mast cells count within the CD117 worsened ICC group (p=0.007). Conclusion No significant increase in the number of mast cells count seen in patients who received a GES may indicate an improvement in overall inflammation in patients with refractory gastroparesis after GES placement.
Identifiants
pubmed: 33329956
doi: 10.7759/cureus.11458
pmc: PMC7733771
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e11458Informations de copyright
Copyright © 2020, Pontikos et al.
Déclaration de conflit d'intérêts
Dr. Abell is the founder of ADEPT-GI, which holds intellectual property covering some aspects of technology in this manuscript.
Références
Neurogastroenterol Motil. 2019 Mar;31(3):e13534
pubmed: 30706646
J Clin Gastroenterol. 2019 May/Jun;53(5):366-372
pubmed: 29672439
Neurogastroenterol Motil. 2009 Oct;21(10):1095-e92
pubmed: 19566589
Annu Rev Physiol. 1999;61:45-84
pubmed: 10099682
J Physiol. 2006 Nov 1;576(Pt 3):659-65
pubmed: 16873400
Clin Gastroenterol Hepatol. 2011 Apr;9(4):314-319.e1
pubmed: 21185396
Gastroenterology. 2018 Jun;154(8):2122-2136.e12
pubmed: 29501441
Gastroenterol Hepatol (N Y). 2010 Dec;6(12):772-7
pubmed: 21301631
Neurogastroenterol Motil. 2006 Jan;18(1):6-17
pubmed: 16371078
World J Gastroenterol. 2016 Jun 21;22(23):5353-63
pubmed: 27340351
Neuromodulation. 2012 May-Jun;15(3):224-31; discussion 231
pubmed: 22364275
Biochim Biophys Acta. 2012 Jan;1822(1):21-33
pubmed: 21185371
Gastroenterol Res Pract. 2018 Nov 13;2018:6309157
pubmed: 30538740